Time filter

Source Type

Zhang P.,Shanghai University | Zhang P.,Zhejiang University | Zhang P.,Shanghai Allist Pharmaceuticals Inc. | Han H.,Shanghai University
Colloids and Surfaces A: Physicochemical and Engineering Aspects | Year: 2012

Compact PEGylated polymer-caged quantum dots were prepared by covalently cross-linking the surface ligands using bifunctional poly(ethylene glycol). CdSe/ZnSe/ZnS quantum dots prepared in organic solvent via conventional synthesis method were firstly transferred to water phase by surface ligands exchange with glutathione molecules, and then cross-linked by bifunctional PEG through the carboxyl-amine coupling by carbodiimide method. Compared with small molecules capped QDs, polymer-caged QDs using PEG crosslinker have shown improved colloidal and pH stability, lower cell toxicity and non-specific binding, and still maintain compact hydrodynamic diameters (<15. nm) and monodispersity. This surface crosslinking strategy can also be used to improve the stability of other similar nanoparticles. © 2012 Elsevier B.V.


The present invention relates to polymorphic forms of N-{4-[3-chloro-4-(3-fluoro-benzyloxy)phenylamino]-quinazolin-6-yl}-acrylamide p-toluenesulfonate with the characteristic X-ray powder diffraction data as stated in the description, preparation methods thereof, pharmaceutical compositions comprising the same and the use thereof.


Patent
Shanghai Allist Pharmaceuticals Inc. | Date: 2011-03-09

The present invention provides a pharmaceutical composition, useful for the treatment of diseases characterized by abnormal PTKs activity of erbB family in a mammal, comprising pharmaceutically acceptable salts of N-{4-[3-chloro-4-(3-fluoro-benzyloxy) phenylamino]quinazolin-6-yl}-acrylamide, optionally a pharmaceutically applicable carrier or diluent, and a stabilizer having a dispersing and/or protective effect on the active ingredient. The present invention further provides a pharmaceutical formulation comprising said composition, methods for preparation of said composition and said formulation, as well as use of said composition and said formulation for treating diseases characterized by abnormal PTKs activity of erbB family in a mammal.


Patent
Shanghai Allist Pharmaceuticals Inc. | Date: 2011-10-27

The present invention relates to a C-aryl glucoside derivative of Formula (I) below, a preparation method therefor and a use thereof, wherein X, R^(1), R^(2), R^(3), R^(4), m and n are as defined in specification. The derivative of the present invention is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor associated with glucose reabsorption of bowel or kidney, and has a good urine glucose excreting effect, thus being useful as a therapeutic agent for treating diabetes and related diseases.


Patent
Shanghai Allist Pharmaceuticals Inc. | Date: 2010-11-10

The present invention has disclosed a compound of formula I and a pharmaceutically acceptable salt or a solvate thereof, wherein the substituents are as defined in the description. The invention has also disclosed a method for preparing the compound of formula I, the pharmaceutical compositions comprising the same and their uses in the preparation of an anti-tumor medicament.


Patent
Shanghai Allist Pharmaceuticals Inc. | Date: 2014-11-26

The present invention refers to aminoheteroaryl compounds of the following formula (I) as well as the preparation method and use thereof, wherein R^(1) and R^(3) are defined in the Description in details. The aminoheteroaryl compounds of the present invention are inhibitors of hepatocyte growth factor receptor (c-Met), have favorable inhibitory effect against c-Met and inhibitory effect against the proliferation of cancer cells, such that they may be used as therapeutic agents for the treatment of tumors and related diseases.


Patent
Shanghai Allist Pharmaceuticals Inc. | Date: 2011-06-14

he present invention has disclosed a compound of formula I and a pharmaceutically acceptable salt or a solvate thereof, wherein the substituents are as defined in the description. The invention has also disclosed a method for preparing the compound of formula I, the pharmaceutical compositions comprising the same and their uses in the preparation of an anti-tumor medicament.


Patent
Shanghai Allist Pharmaceuticals Inc. | Date: 2010-08-04

The invention discloses the crystalline imidazole-5-carboxylic acid derivative (I, the chemical name: 2-butyl-4-chloro-1-[2-(1H-tetrazol-5-yl) 1,1-biphenyl-methyl]-imidazole-5-carboxylic acid, 1-[(isopropoxy)-carbonyloxy] methyl ester), its preparation method and uses thereof.


Patent
Shanghai Allist Pharmaceuticals Inc. | Date: 2013-01-17

The present invention refers to aminoheteroaryl compounds of the following formula (I) as well as the preparation method and use thereof, wherein R^(1 )and R^(3 )are defined in the Description in details. The aminoheteroaryl compounds of the present invention are inhibitors of hepatocyte growth factor receptor (c-Met), have favorable inhibitory effect against c-Met and inhibitory effect against the proliferation of cancer cells, such that they may be used as therapeutic agents for the treatment of tumors and related diseases.


Patent
Shanghai Allist Pharmaceuticals Inc. | Date: 2013-09-04

The present invention relates to a C-aryl glucoside derivative of Formula (I) below, a preparation method therefor and a use thereof, wherein X, R^(1), R^(2), R^(3), R^(4), m and n are as defined in specification. The derivative of the present invention is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor associated with glucose reabsorption of bowel or kidney, and has a good urine glucose excreting effect, thus being useful as a therapeutic agent for treating diabetes and related diseases.

Loading Shanghai Allist Pharmaceuticals Inc. collaborators
Loading Shanghai Allist Pharmaceuticals Inc. collaborators